Cite
HARVARD Citation
Lee, S. et al. (n.d.). 2361 Modified FOLFIRINOX (5-FU/LV, irinotecan and oxaliplatin) as second-line chemotherapy for gemcitabine-resistant or -refractory advanced pancreatic cancer. European journal of cancer. pp. S456-. [Online].